Intelligence for IBD, GI & Colorectal Specialists

Inflammatory bowel disease trials
recruiting in the United States

Up-to-date overview of clinical trials in Crohn's disease, ulcerative colitis, and other forms of inflammatory bowel disease (IBD) recruiting patients in the United States — automatically compiled from ClinicalTrials.gov. Refer eligible patients to participating research centers.

Active trials

1176

US sites

Indications covered

BR trials

Loading map…

94 studies found

Fase 1Crohn DiseaseUS 2 sites in the US

Autologous Stem Cell Transplantation With CD34-Selected Peripheral Blood Stem Cells (PBSC) in Pediatric and Adult Patients With Severe Crohn's Disease

Paul Szabolcs

📍 Pittsburgh👥 20 participants📅 Completion: 2027-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Doenca de CrohnUS 1 site in the US

An Open-Label, Proof of Concept Study of Vorinostat for the Treatment of Moderate-to-Severe Crohn's Disease and Maintenance Therapy With Ustekinumab

National Institute of Allergy and Infectious Diseases (NIAID)

📍 Bethesda👥 35 participants📅 Completion: 2026-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Crohn DiseaseUS 1 site in the US

Maintenance in Autologous Stem Cell Transplant for Crohn's Disease (MASCT - CD)

Aaron Etra

📍 New York👥 50 participants📅 Completion: 2028-10

View details →Refer patient →ClinicalTrials.gov ↗

N/DColite UlcerativaUS 1 site in the US

The Influence of a Fasting Mimicking Diet on Ulcerative Colitis

Stanford University

📍 Palo Alto👥 75 participants📅 Completion: 2028-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Crohn DiseaseUS 1 site in the US

Autologous Hematopoietic Stem Cell Transplantation for Refractory Crohn's Disease

Cedars-Sinai Medical Center

📍 Los Angeles👥 15 participants📅 Completion: 2027-09

View details →Refer patient →ClinicalTrials.gov ↗

N/DDoenca de CrohnColite UlcerativaUS 1 site in the US

University of Pittsburgh Medical Center (UPMC) Center for Inflammatory Bowel Disease (IBD) Research Registry

University of Pittsburgh

📍 Pittsburgh👥 5000 participants📅 Completion: 2030-05

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Crohn DiseaseUS 3 sites in the US

Low Dose IL-2 for the Treatment of Crohn's Disease

Boston Children's Hospital

📍 Boston, New York👥 30 participants📅 Completion: 2027-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4Ulcerative ColitisUS 4 sites in the US

A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets n Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis

Bausch Health Americas, Inc.

📍 Garden Grove, Greenville, Indianapolis, The Bronx👥 70 participants📅 Completion: 2027-06

View details →Refer patient →ClinicalTrials.gov ↗

N/DCrohn DiseaseUlcerative ColitisColite IndeterminadaUS 1 site in the US

Implementation of High Dose Interval Vitamin D Supplementation in Patients With Inflammatory Bowel Disease Receiving Infliximab or Vedolizumab

Boston Children's Hospital

📍 Boston👥 50 participants📅 Completion: 2025-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Ulcerative ColitisUS 1 site in the US

A Phase 2a, Randomized, Double-blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lyophilized Fecal Microbiota Transplantation (PRIM-DJ2727) Administered Orally in Combination With Standard of Care Therapy for Prevention of Relapse or Intestinal Inflammation in Adults With Ulcerative Colitis

The University of Texas Health Science Center, Houston

📍 Houston👥 58 participants📅 Completion: 2027-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DColite UlcerativaDoenca de CrohnArtrite ReumatoideUS 1 site in the US

Regulation of Mucosal Healing in Inflammatory Bowel Disease

Terrence A Barrett

📍 Lexington👥 60 participants📅 Completion: 2026-06

View details →Refer patient →ClinicalTrials.gov ↗

N/DCrohn DiseaseUlcerative ColitisInflammatory Bowel Disease UnclassifiedUS 1 site in the US

Registry and Biorepository for the Study of Inflammatory Bowel Diseases in Central Texas

University of Texas at Austin

📍 Austin👥 1000 participants📅 Completion: 2030-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Colite UlcerativaObesidadeUS 1 site in the US

Pharmacologic Weight Loss as Adjunct Therapy for Ulcerative Colitis in Obese Patients: A Phase 2A, Randomized, Placebo-Controlled Trial

University of California, San Diego

📍 La Jolla👥 40 participants📅 Completion: 2024-06

View details →Refer patient →ClinicalTrials.gov ↗

N/DMelanomaDoenca Inflamatoria IntestinalArtrite ReumatoideUS 1 site in the US

Testing of an Educational Tool for Patients With Melanoma and Concomitant Autoimmune Disease Who Are Candidates for Adjuvant Therapy With Immune Checkpoint Inhibitors: Acceptability and Usability With Patients and Providers

M.D. Anderson Cancer Center

📍 Houston👥 125 participants📅 Completion: 2027-02

View details →Refer patient →ClinicalTrials.gov ↗

N/DPlaque PsoriasisArtrite PsoriasicaDoenca de CrohnUS 1 site in the US

Risankizumab Pregnancy Exposure Registry: a Prospective Observational Study on the Safety of Risankizumab Exposure in Pregnant Women and Their Offspring

AbbVie

📍 Morrisville👥 818 participants📅 Completion: 2032-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Ulcerative ColitisUS 1 site in the US

Butyrate Therapy in Hispanic Children With Ulcerative Colitis

Children's Hospital Los Angeles

📍 Los Angeles👥 10 participants📅 Completion: 2027-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Colite UlcerativaUS 12 sites in the US

An Open-Label, Single-Arm Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of Etrasimod in Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

Pfizer

📍 Abilene, Boston, Chicago, Cleveland, Garden Grove, Orlando, Royal Oak, San Francisco👥 36 participants📅 Completion: 2033-07

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Colite UlcerativaDoenca de CrohnUS 2 sites in the US

A Phase 3b Extension Study to Evaluate the Long-term Safety of Vedolizumab Intravenous in Pediatric Patients With Ulcerative Colitis or Crohn's Disease

Takeda

📍 Minneapolis, Phoenix👥 240 participants📅 Completion: 2031-08

View details →Refer patient →ClinicalTrials.gov ↗

N/DColite UlcerativaUS 1 site in the US

Nicotinamide Riboside in Ulcerative Colitis

University of Pittsburgh

📍 Pittsburgh👥 40 participants📅 Completion: 2026-06

View details →Refer patient →ClinicalTrials.gov ↗

N/DDoenca de CrohnColite UlcerativaUS 2 sites in the US

Bright Light Therapy in Crohn's Disease on Intestinal Barrier Homeostasis

Rush University Medical Center

📍 Charleston, Chicago👥 30 participants📅 Completion: 2026-05

View details →Refer patient →ClinicalTrials.gov ↗

N/DAge Related Macular DegenerationAllergiesAlpha Gal SyndromeUS 1 site in the US

A Single-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

Sanguine Biosciences

📍 Waltham👥 20000 participants📅 Completion: 2025-10

View details →Refer patient →ClinicalTrials.gov ↗

N/DObesityColite UlcerativaUS 1 site in the US

Endoscopic Sleeve Gastroplasty (ESG) as a Treatment Option for Obesity in Ulcerative Colitis (UC) Patients Undergoing Colectomy With Ileal Pouch Anal Anastomosis (IPAA)

Mayo Clinic

📍 Rochester👥 12 participants📅 Completion: 2027-01

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4Crohn DiseaseUS 22 sites in the US

Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease

Connecticut Children's Medical Center

📍 Ann Arbor, Atlanta, Baltimore, Boston, Charlotte, Cincinnati, Cleveland, Columbus👥 900 participants📅 Completion: 2029-07

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Colite Ulcerativa AtivaUS 1 site in the US

A Randomized, Open-label, Pilot Study to Evaluate the Fecal Microbiota Transplantation (FMT) in the Treatment of Ulcerative Colitis

The University of Texas Health Science Center, Houston

📍 Houston👥 20 participants📅 Completion: 2027-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DCrohn DiseaseUS 1 site in the US

A Pilot Study Examining Low Sulfur Diet as Treatment for Persistent Symptoms in Quiescent Crohn's Disease

University of Michigan

📍 Ann Arbor👥 20 participants📅 Completion: 2027-04

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4Colite Ulcerativa Aguda GraveUS 1 site in the US

A Sequential Multiple Assignment Randomized Trial (SMART) Feasibility Pilot Developing and Optimizing Patient-Tailored Adaptive Treatment Strategies (ATS) for Acute Severe Ulcerative Colitis (ASUC)

Berinstein, Jeffrey

📍 Ann Arbor👥 162 participants📅 Completion: 2026-05

View details →Refer patient →ClinicalTrials.gov ↗

N/DCrohn DiseaseInsoniaUS 1 site in the US

RISE: A Remote Study of Insomnia Treatment in Crohn's Disease

Dartmouth-Hitchcock Medical Center

📍 Lebanon👥 83 participants📅 Completion: 2026-11

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Ulcerative ColitisUS 37 sites in the US

A Phase 2, Double-Blinded, Randomized, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of GS-5290 in Participants With Moderately to Severely Active Ulcerative Colitis

Gilead Sciences

📍 Boerne, Canton, Chesapeake, Chula Vista, Columbus, Coral Gables, Coronado, Dayton👥 176 participants📅 Completion: 2028-02

View details →Refer patient →ClinicalTrials.gov ↗

N/DColite UlcerativaDoenca de CrohnDoenca Inflamatoria IntestinalUS 1 site in the US

Development of a Therapeutic Endpoint in Pediatric IBD Conditions

Children's National Research Institute

📍 Washington D.C.👥 60 participants📅 Completion: 2027-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4Colite UlcerativaUS 39 sites in the US

An Open-Label, Phase 4, Single-Arm, Multicenter Study to Evaluate the Induction of Response and Remission of Vedolizumab Dual Targeted Therapy With Tofacitinib in Adult Patients With Moderately to Severely Active Ulcerative Colitis

Takeda

📍 Asheville, Chapel Hill, Chevy Chase, Chicago, Cincinnati, Columbus, Dallas, Dothan👥 65 participants📅 Completion: 2027-07

View details →Refer patient →ClinicalTrials.gov ↗

N/DCrohn DiseaseUS 1 site in the US

Reverse-Engineering of Exclusive Enteral Nutrition (RE-EEN) in Crohn's Disease: A Multi-Center Trial

Seattle Children's Hospital

📍 Seattle👥 60 participants📅 Completion: 2030-01

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Crohn DiseaseUS 10 sites in the US

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Active Dose Regimens of MORF-057 in Adults With Moderately to Severely Active Crohn's Disease (GARNET)

Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)

📍 Cedar Park, Houston, Johnson City, Lancaster, Lynchburg, Ogden, Raleigh, San Marcos👥 385 participants📅 Completion: 2030-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Crohn DiseaseUS 3 sites in the US

A Randomized, Double-Blind, Phase 3b Study to Evaluate the Short- and Long-Term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab and Oral Placebo for Induction Followed by Intravenous Vedolizumab Monotherapy for Maintenance in the Treatment of Adults With Moderately to Severely Active Crohn's Disease

Takeda

📍 Colorado Springs, San Antonio, Tyler👥 396 participants📅 Completion: 2028-08

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Crohn DiseaseUS 26 sites in the US

A Phase 2b, Multicenter, Randomized, Double-Blind Induction, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Crohn's Disease

Takeda

📍 Atlanta, Bellaire, Clearwater, Decatur, Fort Worth, Glen Burnie, Greenville, Iowa City👥 268 participants📅 Completion: 2027-07

View details →Refer patient →ClinicalTrials.gov ↗

N/DCrohn DiseaseUS 11 sites in the US

VOICE-Characterization of Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease Using Patient-Reported Outcome Measures: A Prospective Observational Study

Alimentiv Inc.

📍 Bellevue, Chapel Hill, Chestnut Hill, Cleveland, Evanston, Fort Worth, Iowa City, Mansfield👥 300 participants📅 Completion: 2026-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Ulcerative ColitisUS 15 sites in the US

A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis

Takeda

📍 Atlanta, Bellaire, Clearwater, Decatur, Glen Burnie, Greenville, Lakeland, Las Vegas👥 207 participants📅 Completion: 2027-08

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Crohn DiseaseUS 1 site in the US

A Prospective, Randomized, Placebo-controlled Trial of Fluconazole in Combination With IL-23 Therapy Versus IL-23 Therapy Alone for the Treatment of Crohn's Disease

Weill Medical College of Cornell University

📍 New York👥 120 participants📅 Completion: 2029-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DUlcerative ColitisUS 1 site in the US

High Dimensional Mass Cytometry as a Tool to Understand Ozanimod's Mechanism of Action (MOA)

University of California, San Diego

📍 San Diego👥 10 participants📅 Completion: 2026-09

View details →Refer patient →ClinicalTrials.gov ↗

N/DCrohn DiseaseColite UlcerativaColite IndeterminadaUS 1 site in the US

Seattle Spatial Transcriptomic Research in Inflammatory Bowel Disease Evaluation

Seattle Children's Hospital

📍 Seattle👥 200 participants📅 Completion: 2030-01

View details →Refer patient →ClinicalTrials.gov ↗

N/DColite UlcerativaUS 14 sites in the US

A Multi-Center, Prospective, Non-Interventional Study of Real-World Effectiveness of Etrasimod in Patients With Ulcerative Colitis (ENDEAVOUR-UC)

Pfizer

📍 Chapel Hill, Chevy Chase, Cincinnati, Glen Burnie, Houston, Littleton, Mesa, New York👥 300 participants📅 Completion: 2028-07

View details →Refer patient →ClinicalTrials.gov ↗

N/DUlcerative ColitisCrohn DiseaseUS 1 site in the US

The Clinical and Microbial Impact of Prebiotics in Ulcerative Colitis

University of California, Los Angeles

📍 Los Angeles👥 70 participants📅 Completion: 2027-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DCrohn DiseaseUS 2 sites in the US

Combination Therapy of Resilience Intervention With Biologics in Crohn's Disease (CATHARSIS Trial)

Icahn School of Medicine at Mount Sinai

📍 New York👥 170 participants📅 Completion: 2028-07

View details →Refer patient →ClinicalTrials.gov ↗

N/DCrohn DiseaseUS 2 sites in the US

Comparison of Conventional Clinical and Abbreviated MR Enterography Protocols in Children and Adults With Crohn's Disease

Children's Hospital Medical Center, Cincinnati

📍 New York, Rochester👥 300 participants📅 Completion: 2028-02

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Crohn DiseaseUS 1 site in the US

Determining the Therapeutic Potential of Statins on Stricturing Crohn's Disease

Stanford University

📍 Stanford👥 20 participants📅 Completion: 2028-10

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Crohn DiseaseUS 58 sites in the US

A Phase 2a Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderate to Severe Crohn's Disease

AbbVie

📍 Asheville, Boise, Cedar Park, Chevy Chase, Chicago, Cincinnati, Clermont, Colorado Springs👥 540 participants📅 Completion: 2028-08

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4Ulcerative ColitisCrohn DiseaseUS 64 sites in the US

A Phase 4 Study Evaluating Moderate to Severely Active Ulcerative Colitis or Crohn's Disease and the Use of Vedolizumab Subcutaneous Within a Community Setting

Takeda

📍 Atlanta, Baton Rouge, Bellevue, Brooksville, Carmel, Chandler, Charlotte, Chevy Chase👥 400 participants📅 Completion: 2028-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Colite UlcerativaUS 34 sites in the US

An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination With Mirikizumab for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis

Eli Lilly and Company

📍 Baytown, Brooklyn, Chapel Hill, Chula Vista, Cincinnati, Colorado Springs, Coronado, Edinburg👥 140 participants📅 Completion: 2028-09

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Ulcerative ColitisUS 16 sites in the US

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study in Healthy Participants Followed by a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study in Participants With Moderate-To-Severe Active Ulcerative Colitis.

Xencor, Inc.

📍 Bradenton, Brandon, Denton, Georgetown, Houston, Jacksonville, Kingwood, Kissimmee👥 270 participants📅 Completion: 2029-01

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Crohn DiseaseUS 1 site in the US

Standardized Microbiota Transplant Therapy in Crohn's Disease

University of Minnesota

📍 Minneapolis👥 120 participants📅 Completion: 2029-06

View details →Refer patient →ClinicalTrials.gov ↗

N/DCrohn DiseaseUS 1 site in the US

A Pilot Study to Assess the Safety, Tolerability, and Efficacy of Virtual Reality for the Treatment of Abdominal Pain in Quiescent Crohn's Disease

Mayo Clinic

📍 Jacksonville👥 15 participants📅 Completion: 2026-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Crohn DiseaseColite UlcerativaUS 12 sites in the US

A Phase 3 Extension Study to Evaluate the Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis

Merck Sharp & Dohme LLC

📍 Bristol, Charlottesville, Garland, Liberty, Lubbock, New York, San Antonio, Southlake👥 1380 participants📅 Completion: 2037-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DDoenca Inflamatoria IntestinalColite UlcerativaDoenca de CrohnUS 1 site in the US

Family Members At INcreased-risk for Developing Inflammatory Bowel Disease (FIND-IBD)

Massachusetts General Hospital

📍 Boston👥 50 participants📅 Completion: 2034-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Crohns DiseaseColite UlcerativaArtrite PsoriasicaUS 4 sites in the US

A Phase 3, Multicenter, Open-label, Basket, LTE Study to Evaluate the Safety of Guselkumab in Pediatric Participants With Crohn's Disease, Ulcerative Colitis, or Juvenile Psoriatic Arthritis

Janssen Research & Development, LLC

📍 Atlanta, Cincinnati, Indianapolis, Salt Lake City👥 196 participants📅 Completion: 2031-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DUlcerative ColitisUS 8 sites in the US

MIrikizumab in UC - a Real-woRld prOspective multicenteR Registry

University of North Carolina, Chapel Hill

📍 Chapel Hill, Charleston, Denver, Iowa City, Louisville, Orlando, Rochester, San Antonio👥 100 participants📅 Completion: 2030-01

View details →Refer patient →ClinicalTrials.gov ↗

N/DColorectal CancerSiboCrohn DiseaseUS 4 sites in the US

Observational Study of Urine Metabolites in the Diagnosis of Disease

Luventix, Inc.

📍 Encinitas, Santa Monica, Walnut Creek👥 1250 participants📅 Completion: 2026-09

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Crohn DiseaseUS 13 sites in the US

A Phase 1/2a, Open Label, Dose Escalation Study to Evaluate the Safety and Preliminary Efficacy of TRX103 in Subjects With Moderate to Severe Treatment-Refractory Crohn's Disease

Tr1X, Inc.

📍 Ann Arbor, Chicago, Cleveland, Gainesville, Iowa City, Louisville, New York, Rochester👥 39 participants📅 Completion: 2027-01

View details →Refer patient →ClinicalTrials.gov ↗

N/DDoenca de CrohnRetocolite UlcerativaUS 2 sites in the US

Real World Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention (MONITOR Study)

Mercy Medical Center

📍 Chapel Hill, New York👥 200 participants📅 Completion: 2026-09

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Crohn DiseaseColite UlcerativaUS 2 sites in the US

A Phase 2, Open-Label Extension Trial to Evaluate the Long-term Safety and Tolerability of Oral Zasocitinib (TAK-279) in Participants With Moderately to Severely Active Ulcerative Colitis and Moderately to Severely Active Crohn's Disease

Takeda

📍 Glen Burnie, Tyler👥 183 participants📅 Completion: 2029-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4Crohn DiseaseUS 1 site in the US

A Randomized Clinical Trial to Determine the Effect of Dual Glucose-dependent Insulinotropic Polypeptide (GIP)/GLP-1 Receptor Agonist-mediated Weight Loss and Diet on Crohn's Disease Clinical Response: a Pilot Study

University of Miami

📍 Miami👥 24 participants📅 Completion: 2027-03

View details →Refer patient →ClinicalTrials.gov ↗

N/DUlcerative ColitisUS 1 site in the US

A Culturally Tailored Anti-inflammatory Diet for American Patients With Ulcerative Colitis

University of Miami

📍 Miami👥 122 participants📅 Completion: 2030-09

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Doenca de CrohnUS 90 sites in the US

A Phase III, Multicenter, Double-Blind, Placebo-Controlled, Treat-Through Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With RO7790121 in Patients With Moderately to Severely Active Crohn's Disease

Hoffmann-La Roche

📍 Arlington, Atlanta, Beavercreek, Boston, Brooksville, Brunswick, Charleston, Charlotte👥 600 participants📅 Completion: 2033-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Crohn DiseaseCrohns DiseaseUS 45 sites in the US

A Phase III, Multicenter, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Induction Therapy With RO7790121 in Patients With Moderately to Severely Active Crohn's Disease

Hoffmann-La Roche

📍 Baltimore, Baton Rouge, Beavercreek, Brooklyn, Charlotte, Chevy Chase, Chicago, Cleveland👥 425 participants📅 Completion: 2033-04

View details →Refer patient →ClinicalTrials.gov ↗

N/DInflammatory Bowel DiseaseUS 1 site in the US

CorEvitas Inflammatory Bowel Disease Pregnancy Registry (IBD-PR)

CorEvitas

📍 Wilmington👥 832 participants📅 Completion: 2032-09

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Doenca de Crohn PerianalUS 3 sites in the US

A Phase 2a Study of Allogeneic Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicle Isolate Product (DB-3Q) in Patients With Perianal Fistulizing Crohn's Disease

Direct Biologics, LLC

📍 Aurora, New York, St Louis👥 36 participants📅 Completion: 2026-10

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Crohn DiseaseObesidade ou SobrepesoUS 33 sites in the US

A Phase 3b, Randomized, Multicenter, Controlled Study of Mirikizumab and Placebo or Mirikizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

Eli Lilly and Company

📍 Anaheim, Chevy Chase, Cordova, Dothan, Fayetteville, Greenville, Idaho Falls, Indianapolis👥 290 participants📅 Completion: 2028-05

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Crohn DiseaseUS 20 sites in the US

A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR442970 in Adults With Moderate to Severe Crohn's Disease

Sanofi

📍 Boston, Chapel Hill, Escondido, Fredericksburg, Harrisburg, Iowa City, Kansas City, Kissimmee👥 99 participants📅 Completion: 2029-10

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Colite UlcerativaUS 21 sites in the US

A Phase 2b, Multi-national, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Followed by a Long-term Extension to Evaluate the Efficacy and Safety of SAR442970 in Adult Participants With Moderate to Severe Ulcerative Colitis

Sanofi

📍 Boston, Chapel Hill, Escondido, Harrisburg, Houston, Iowa City, Jacksonville, Kissimmee👥 99 participants📅 Completion: 2029-10

View details →Refer patient →ClinicalTrials.gov ↗

N/DSaudavelDoenca de CrohnDoenca Inflamatoria IntestinalUS 1 site in the US

Feasibility of a Wireless Thermal Capsule Endoscopy to Detect Gastrointestinal Thermal Variance

Massachusetts General Hospital

📍 Boston👥 10 participants📅 Completion: 2027-04

View details →Refer patient →ClinicalTrials.gov ↗

N/DUlcerative ColitisUS 1 site in the US

Effect of Pomegranate Juice on Gut Inflammation, Quality of Life and the Gut Microbiome in Patients With Ulcerative Colitis: A Pilot Study

University of California, Los Angeles

📍 Los Angeles👥 30 participants📅 Completion: 2027-10

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Crohn DiseaseUS 90 sites in the US

A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Phase 3, Induction Study to Evaluate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

Sanofi

📍 Atlanta, Baton Rouge, Canoga Park, Canton, Chapel Hill, Charlotte, Chesterfield, Clermont👥 980 participants📅 Completion: 2029-05

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Ulcerative ColitisUS 9 sites in the US

A Multicenter, Multinational, Randomized, Double-blind, Placebo-Controlled, Phase 3 Maintenance Study to Evaluate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

Sanofi

📍 Baton Rouge, Columbus, Fort Myers, Kissimmee, Liberty, Miami, Monroe, New York👥 671 participants📅 Completion: 2033-04

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Ulcerative ColitisUS 36 sites in the US

A Phase 2, Multicenter, Randomized, Double-Blind, Active-Controlled Study of LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis

Eli Lilly and Company

📍 Anaheim, Bellevue, Boston, Canton, Cedar Park, Clinton Township, Colorado Springs, Cordova👥 252 participants📅 Completion: 2029-03

View details →Refer patient →ClinicalTrials.gov ↗

N/DCrohn DiseaseUlcerative ColitisIndeterminate ColitisUS 1 site in the US

Evaluation of the SMART IBD App Digital Therapeutic Tool for Pediatric Inflammatory Bowel Disease

Children's Hospital Medical Center, Cincinnati

📍 Cincinnati👥 70 participants📅 Completion: 2027-08

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Crohn DiseaseUS 46 sites in the US

A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol to Evaluate the Efficacy and Safety of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

Janssen Research & Development, LLC

📍 Anaheim, Atlanta, Canoga Park, Carmel, Carrollton, Chandler, Chapel Hill, Chevy Chase👥 1092 participants📅 Completion: 2032-10

View details →Refer patient →ClinicalTrials.gov ↗

N/DCrohn DiseaseUlcerative ColitisIbd UnclassifiedUS 4 sites in the US

Clinical Outcomes of Medications Post Anti-TNF: Researching Effectiveness in Pediatric IBD

University of North Carolina, Chapel Hill

📍 Chapel Hill, Charlotte, Durham, Pittsburgh👥 1100 participants📅 Completion: 2028-09

View details →Refer patient →ClinicalTrials.gov ↗

N/DCrohn DiseaseUlcerative ColitisIbd UnclassifiedUS 1 site in the US

Assessment and Educational Intervention to Reduce Ultra-processed Food Consumption in Pediatric Patients With IBD

Connecticut Children's Medical Center

📍 Hartford👥 120 participants📅 Completion: 2026-07

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4Colite Ulcerativa Aguda GraveUS 1 site in the US

Acute Severe Ulcerative Colitis- Upadacitinib Combined With Corticosteroids vs Corticosteroid Monotherapy Induction While Transitioning Away From the Emergency Setting (ACUTE): A Phase IV, Single Center, Partially Blinded, Randomized Study

Berinstein, Jeffrey

📍 Ann Arbor👥 110 participants📅 Completion: 2030-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Crohn DiseaseFibrose IntestinalUS 1 site in the US

Gallium-68-labeled Fibroblast Activation Protein Inhibitor-46 (68Ga-FAPI-46) PET in Crohn's Disease Patients: a Case-control Study Designed to Illuminate the Spectrum of Fibrostenosis in Patients With Small Bowel Crohn's Disease

Mayo Clinic

📍 Rochester👥 45 participants📅 Completion: 2027-04

View details →Refer patient →ClinicalTrials.gov ↗

N/DCrohn DiseaseDismenorreia PrimariaUS 1 site in the US

Acetaminophen Versus Ibuprofen for Discomfort in Crohn's Disease (AVID-CD): An Open-Label Randomized Pilot Trial

University of North Carolina, Chapel Hill

📍 Chapel Hill👥 24 participants📅 Completion: 2028-07

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Ulcerative ColitisUS 1 site in the US

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety Tolerability, Pharmacokinetics, and Pharmacosymics of Single Ascending Doses of Intravenously Administerted ALTB-268 in Healthy Participants

AltruBio Inc.

📍 Miami👥 24 participants📅 Completion: 2026-07

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Ulcerative ColitisUS 1 site in the US

Selenium Supplementation in Moderate-Severely Active Ulcerative Colitis Patients Treated With Advanced Therapies: A Placebo-Controlled, Double-Blind, Randomized Clinical Trial

Northwestern University

📍 Chicago👥 180 participants📅 Completion: 2028-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DCrohn DiseaseColite UlcerativaArtrite ReumatoideUS 1 site in the US

Effectiveness and Efficacy of a Ketogenic or Carnivore (Lion) Diet for Quality Life and Symptom Burden in Individuals With Symptomatic Inflammatory Bowel Disease or Rheumatoid Arthritis: A Randomized Controlled Clinical Trial

Fuller Research Foundation

📍 Charlottesville👥 160 participants📅 Completion: 2027-09

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Colite UlcerativaDoenca de CrohnUS 9 sites in the US

A Master Protocol for a Phase 3, Multicenter, Open-label, Long-term Extension Study to Evaluate the Long-term Efficacy and Safety of Mirikizumab in Children and Adolescents With Moderate-to-severe Ulcerative Colitis or Crohn's Disease

Eli Lilly and Company

📍 Atlanta, Boston, Fort Worth, Hartford, New York, San Francisco, St Louis, Waltham👥 150 participants📅 Completion: 2030-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Crohn DiseaseUS 11 sites in the US

A Phase 3, Multicenter, Randomized Clinical Study to Evaluate Mirikizumab in Pediatric Crohn's Disease

Eli Lilly and Company

📍 Atlanta, Burlington, Dayton, Fort Worth, Hartford, Indianapolis, New York, Philadelphia👥 90 participants📅 Completion: 2028-04

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Crohn DiseaseUS 13 sites in the US

A Phase 3, Multicenter, Randomized, Platform Study of p19 Inhibition of the IL-23 Pathway to Establish Efficacy in Pediatric Crohn's Disease

Janssen Research & Development, LLC

📍 Atlanta, Boston, Colchester, Dayton, Fort Worth, Hartford, Indianapolis, Los Angeles👥 120 participants📅 Completion: 2028-07

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Crohn DiseaseUS 12 sites in the US

A Phase 3 Multicenter Study to Evaluate Efficacy, Safety, and Pharmacokinetics of Upadacitinib With Open-Label Induction, Randomized, Double-Blind Maintenance and Open-Label Long-Term Extension in Pediatric Subjects With Moderately to Severely Active Crohn's Disease and Inadequate Response, Intolerance, or Medical Contraindications to Corticosteroids, Immunosuppressants, and/or Biologic Therapy

AbbVie

📍 Aurora, Boston, Chapel Hill, Cleveland, Hartford, Indianapolis, Minneapolis, New York👥 110 participants📅 Completion: 2034-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Crohn DiseaseUS 2 sites in the US

A Phase 3b, Open-label, Multicenter Study to Evaluate Transmural Healing and Disease Modifying Effect of Guselkumab in Crohn's Disease Patients

Janssen-Cilag Ltd.

📍 Charleston, San Francisco👥 112 participants📅 Completion: 2028-03

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Crohn DiseaseUS 75 sites in the US

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Moderately to Severely Active Crohn's Disease

Merck Sharp & Dohme LLC

📍 Anaheim, Ann Arbor, Atlanta, Aurora, Bellevue, Bethesda, Boston, Chapel Hill👥 1200 participants📅 Completion: 2029-11

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Colite UlcerativaUS 67 sites in the US

A Phase III, Multicenter, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Induction Therapy With RO7790121 in Patients With Moderately to Severely Active Ulcerative Colitis

Hoffmann-La Roche

📍 Apple Valley, Atlanta, Beavercreek, Brooklyn, Charlotte, Chesapeake, Cincinnati, Cleveland👥 350 participants📅 Completion: 2031-01

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Crohn DiseaseUS 18 sites in the US

A Phase 2, Multinational, Multicenter, Randomized, Doubleblind, Placebocontrolled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR441566 in Adults With Moderate to Severe Crohn's Disease.

Sanofi

📍 Ann Arbor, Bristol, Clermont, Flowood, Glenview, Greenville, Gurnee, Homestead👥 260 participants📅 Completion: 2029-05

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Colite UlcerativaUS 18 sites in the US

A Phase 2, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR441566 in Adults With Moderate-to-severe Ulcerative Colitis

Sanofi

📍 Ann Arbor, Bristol, Clermont, Glenview, Gurnee, Katy, Kissimmee, Lima👥 204 participants📅 Completion: 2028-05

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Ulcerative ColitisObesidade ou SobrepesoUS 36 sites in the US

A Phase 3b, Randomized, Multicenter, Controlled Study of Mirikizumab and Placebo or Mirikizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight

Eli Lilly and Company

📍 Anaheim, Chevy Chase, Chicago, Cordova, Dothan, Fayetteville, Greenville, Idaho Falls👥 350 participants📅 Completion: 2028-04

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Colite UlcerativaUS 6 sites in the US

A Phase IIb, Multicenter, Double-blind, Placebo-controlled Induction Study With an Active Treatment Extension to Assess the Efficacy, Safety, and Pharmacokinetics of RO7837195 in Patients With Moderately to Severely Active Ulcerative Colitis

Genentech, Inc.

📍 Colorado Springs, Fresh Meadows, Kissimmee, Lancaster, Monroe, San Diego👥 224 participants📅 Completion: 2028-10

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Colite UlcerativaUS 46 sites in the US

A Phase 3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol in Adults With an Open Label Study in Adolescents to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy With Icotrokinra in Participants With Moderately to Severely Active Ulcerative Colitis

Janssen Research & Development, LLC

📍 Anaheim, Atlanta, Austin, Carmel, Carrollton, Chandler, Chapel Hill, Charlotte👥 882 participants📅 Completion: 2032-01

View details →Refer patient →ClinicalTrials.gov ↗

Questions or requests?

Data deletion (LGPD/GDPR), partnerships, referrals, or any other matter.

Inflammatory bowel disease trialsrecruiting in the United States

Autologous Stem Cell Transplantation With CD34-Selected Peripheral Blood Stem Cells (PBSC) in Pediatric and Adult Patients With Severe Crohn's Disease

An Open-Label, Proof of Concept Study of Vorinostat for the Treatment of Moderate-to-Severe Crohn's Disease and Maintenance Therapy With Ustekinumab

Maintenance in Autologous Stem Cell Transplant for Crohn's Disease (MASCT - CD)

The Influence of a Fasting Mimicking Diet on Ulcerative Colitis

Autologous Hematopoietic Stem Cell Transplantation for Refractory Crohn's Disease

University of Pittsburgh Medical Center (UPMC) Center for Inflammatory Bowel Disease (IBD) Research Registry

Low Dose IL-2 for the Treatment of Crohn's Disease

A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets n Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis

Implementation of High Dose Interval Vitamin D Supplementation in Patients With Inflammatory Bowel Disease Receiving Infliximab or Vedolizumab

Regulation of Mucosal Healing in Inflammatory Bowel Disease

Registry and Biorepository for the Study of Inflammatory Bowel Diseases in Central Texas

Pharmacologic Weight Loss as Adjunct Therapy for Ulcerative Colitis in Obese Patients: A Phase 2A, Randomized, Placebo-Controlled Trial

Testing of an Educational Tool for Patients With Melanoma and Concomitant Autoimmune Disease Who Are Candidates for Adjuvant Therapy With Immune Checkpoint Inhibitors: Acceptability and Usability With Patients and Providers

Risankizumab Pregnancy Exposure Registry: a Prospective Observational Study on the Safety of Risankizumab Exposure in Pregnant Women and Their Offspring

Butyrate Therapy in Hispanic Children With Ulcerative Colitis

An Open-Label, Single-Arm Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of Etrasimod in Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

A Phase 3b Extension Study to Evaluate the Long-term Safety of Vedolizumab Intravenous in Pediatric Patients With Ulcerative Colitis or Crohn's Disease

Nicotinamide Riboside in Ulcerative Colitis

Bright Light Therapy in Crohn's Disease on Intestinal Barrier Homeostasis

A Single-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

Endoscopic Sleeve Gastroplasty (ESG) as a Treatment Option for Obesity in Ulcerative Colitis (UC) Patients Undergoing Colectomy With Ileal Pouch Anal Anastomosis (IPAA)

Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease

A Randomized, Open-label, Pilot Study to Evaluate the Fecal Microbiota Transplantation (FMT) in the Treatment of Ulcerative Colitis

A Pilot Study Examining Low Sulfur Diet as Treatment for Persistent Symptoms in Quiescent Crohn's Disease

A Sequential Multiple Assignment Randomized Trial (SMART) Feasibility Pilot Developing and Optimizing Patient-Tailored Adaptive Treatment Strategies (ATS) for Acute Severe Ulcerative Colitis (ASUC)

RISE: A Remote Study of Insomnia Treatment in Crohn's Disease

A Phase 2, Double-Blinded, Randomized, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of GS-5290 in Participants With Moderately to Severely Active Ulcerative Colitis

Development of a Therapeutic Endpoint in Pediatric IBD Conditions

An Open-Label, Phase 4, Single-Arm, Multicenter Study to Evaluate the Induction of Response and Remission of Vedolizumab Dual Targeted Therapy With Tofacitinib in Adult Patients With Moderately to Severely Active Ulcerative Colitis

Reverse-Engineering of Exclusive Enteral Nutrition (RE-EEN) in Crohn's Disease: A Multi-Center Trial

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Active Dose Regimens of MORF-057 in Adults With Moderately to Severely Active Crohn's Disease (GARNET)

A Phase 2b, Multicenter, Randomized, Double-Blind Induction, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Crohn's Disease

VOICE-Characterization of Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease Using Patient-Reported Outcome Measures: A Prospective Observational Study

A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis

A Prospective, Randomized, Placebo-controlled Trial of Fluconazole in Combination With IL-23 Therapy Versus IL-23 Therapy Alone for the Treatment of Crohn's Disease

High Dimensional Mass Cytometry as a Tool to Understand Ozanimod's Mechanism of Action (MOA)

Seattle Spatial Transcriptomic Research in Inflammatory Bowel Disease Evaluation

A Multi-Center, Prospective, Non-Interventional Study of Real-World Effectiveness of Etrasimod in Patients With Ulcerative Colitis (ENDEAVOUR-UC)

The Clinical and Microbial Impact of Prebiotics in Ulcerative Colitis

Combination Therapy of Resilience Intervention With Biologics in Crohn's Disease (CATHARSIS Trial)

Comparison of Conventional Clinical and Abbreviated MR Enterography Protocols in Children and Adults With Crohn's Disease

Determining the Therapeutic Potential of Statins on Stricturing Crohn's Disease

A Phase 2a Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderate to Severe Crohn's Disease

A Phase 4 Study Evaluating Moderate to Severely Active Ulcerative Colitis or Crohn's Disease and the Use of Vedolizumab Subcutaneous Within a Community Setting

An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination With Mirikizumab for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study in Healthy Participants Followed by a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study in Participants With Moderate-To-Severe Active Ulcerative Colitis.

Standardized Microbiota Transplant Therapy in Crohn's Disease

A Pilot Study to Assess the Safety, Tolerability, and Efficacy of Virtual Reality for the Treatment of Abdominal Pain in Quiescent Crohn's Disease

A Phase 3 Extension Study to Evaluate the Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis

Family Members At INcreased-risk for Developing Inflammatory Bowel Disease (FIND-IBD)

A Phase 3, Multicenter, Open-label, Basket, LTE Study to Evaluate the Safety of Guselkumab in Pediatric Participants With Crohn's Disease, Ulcerative Colitis, or Juvenile Psoriatic Arthritis

MIrikizumab in UC - a Real-woRld prOspective multicenteR Registry

Observational Study of Urine Metabolites in the Diagnosis of Disease

A Phase 1/2a, Open Label, Dose Escalation Study to Evaluate the Safety and Preliminary Efficacy of TRX103 in Subjects With Moderate to Severe Treatment-Refractory Crohn's Disease

Real World Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention (MONITOR Study)

A Phase 2, Open-Label Extension Trial to Evaluate the Long-term Safety and Tolerability of Oral Zasocitinib (TAK-279) in Participants With Moderately to Severely Active Ulcerative Colitis and Moderately to Severely Active Crohn's Disease

A Randomized Clinical Trial to Determine the Effect of Dual Glucose-dependent Insulinotropic Polypeptide (GIP)/GLP-1 Receptor Agonist-mediated Weight Loss and Diet on Crohn's Disease Clinical Response: a Pilot Study

A Culturally Tailored Anti-inflammatory Diet for American Patients With Ulcerative Colitis

A Phase III, Multicenter, Double-Blind, Placebo-Controlled, Treat-Through Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With RO7790121 in Patients With Moderately to Severely Active Crohn's Disease

A Phase III, Multicenter, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Induction Therapy With RO7790121 in Patients With Moderately to Severely Active Crohn's Disease

CorEvitas Inflammatory Bowel Disease Pregnancy Registry (IBD-PR)

A Phase 2a Study of Allogeneic Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicle Isolate Product (DB-3Q) in Patients With Perianal Fistulizing Crohn's Disease

A Phase 3b, Randomized, Multicenter, Controlled Study of Mirikizumab and Placebo or Mirikizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR442970 in Adults With Moderate to Severe Crohn's Disease

A Phase 2b, Multi-national, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Followed by a Long-term Extension to Evaluate the Efficacy and Safety of SAR442970 in Adult Participants With Moderate to Severe Ulcerative Colitis

Feasibility of a Wireless Thermal Capsule Endoscopy to Detect Gastrointestinal Thermal Variance

Effect of Pomegranate Juice on Gut Inflammation, Quality of Life and the Gut Microbiome in Patients With Ulcerative Colitis: A Pilot Study

A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Phase 3, Induction Study to Evaluate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

A Multicenter, Multinational, Randomized, Double-blind, Placebo-Controlled, Phase 3 Maintenance Study to Evaluate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

A Phase 2, Multicenter, Randomized, Double-Blind, Active-Controlled Study of LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis

Evaluation of the SMART IBD App Digital Therapeutic Tool for Pediatric Inflammatory Bowel Disease

A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol to Evaluate the Efficacy and Safety of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

Clinical Outcomes of Medications Post Anti-TNF: Researching Effectiveness in Pediatric IBD

Assessment and Educational Intervention to Reduce Ultra-processed Food Consumption in Pediatric Patients With IBD

Acute Severe Ulcerative Colitis- Upadacitinib Combined With Corticosteroids vs Corticosteroid Monotherapy Induction While Transitioning Away From the Emergency Setting (ACUTE): A Phase IV, Single Center, Partially Blinded, Randomized Study

Gallium-68-labeled Fibroblast Activation Protein Inhibitor-46 (68Ga-FAPI-46) PET in Crohn's Disease Patients: a Case-control Study Designed to Illuminate the Spectrum of Fibrostenosis in Patients With Small Bowel Crohn's Disease

Acetaminophen Versus Ibuprofen for Discomfort in Crohn's Disease (AVID-CD): An Open-Label Randomized Pilot Trial

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety Tolerability, Pharmacokinetics, and Pharmacosymics of Single Ascending Doses of Intravenously Administerted ALTB-268 in Healthy Participants

Selenium Supplementation in Moderate-Severely Active Ulcerative Colitis Patients Treated With Advanced Therapies: A Placebo-Controlled, Double-Blind, Randomized Clinical Trial

Inflammatory bowel disease trials
recruiting in the United States